Drug clearance by aldehyde oxidase: can we avoid clinical failure?

References

• Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D. 2012. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 69(1):221–227.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Joswig-Jones CA, Jones JP. 2020. Site-directed mutagenesis at the molybdenum pterin cofactor site of the human aldehyde oxidase: interrogating the kinetic differences between human and cynomolgus monkey. Drug Metab Dispos. 48(12):1364–1371.
   PubMed Web of Science ®Google Scholar
• Adusumalli S, Jamwal R, Obach RS, Ryder TF, Leggio L, Akhlaghi F. 2019. Role of molybdenum-containing enzymes in the biotransformation of the novel ghrelin receptor inverse agonist PF-5190457: a reverse translational bed-to-bench approach. Drug Metab Dispos. 47(8):874–882.
   PubMed Web of Science ®Google Scholar
• Alfaro JF, Joswig-Jones CA, Ouyang W, Nichols J, Crouch GJ, Jones JP. 2009. Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli. Drug Metab Dispos. 37(12):2393–2398.
   PubMed Web of Science ®Google Scholar
• Allen CE, Doll MA, Hein DW. 2017. N-Acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 45(12):1276–1281.
   PubMed Web of Science ®Google Scholar
• Anderson LW, Collins JM, Klecker RW, Katki AG, Parchment RE, Boinpally RR, LoRusso PM, Ivy SP. 2005. Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions. Cancer Chemother Pharmacol. 56(4):351–357.
   PubMed Web of Science ®Google Scholar
• Asano T, Ikegaki I, Satoh S, Seto M, Sasaki Y. 1998. A protein kinase inhibitor, Fasudil (AT-877): a novel approach to signal transduction therapy. Cardiovasc Drug Reviews. 16(1):76–87.
   Web of Science ®Google Scholar
• Austin RP, Barton P, Mohmed S, Riley RJ. 2005. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos. 33(3):419–425.
   PubMed Web of Science ®Google Scholar
• Bagal SK, Andrews M, Bechle BM, Bian J, Bilsland J, Blakemore DC, Braganza JF, Bungay PJ, Corbett MS, Cronin CN, et al. 2018. Discovery of potent, selective, and peripherally restricted pan-Trk kinase inhibitors for the treatment of pain. J Med Chem. 61(15):6779–6800.
   PubMed Web of Science ®Google Scholar
• Baldwin SJ, Clarke SE, Chenery RJ. 1999. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 48(3):424–432.
   PubMed Web of Science ®Google Scholar
• Barr JT, Choughule KV, Nepal S, Wong T, Chaudhry AS, Joswig-Jones CA, Zientek M, Strom SC, Schuetz EG, Thummel KE, et al. 2014. Why do most human liver cytosol preparations lack xanthine oxidase activity? Drug Metab Dispos. 42(4):695–699.
   PubMed Web of Science ®Google Scholar
• Basit A, Fan PW, Khojasteh SC, Murray BP, Smith BJ, Heyward S, Prasad B. 2022. Comparison of tissue abundance of non-cytochrome P450 drug-metabolizing enzymes by quantitative proteomics between humans and laboratory animal species. Drug Metab Dispos. 50(3):197–203.
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, Fernando D, Gao H, Hepworth D, Jackson VM, et al. 2014. Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate. ACS Med Chem Lett. 5(5):474–479.
   PubMed Web of Science ®Google Scholar
• Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, et al. 2012. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 106(10):1598–1604.
   PubMed Web of Science ®Google Scholar
• Bowman CM, Benet LZ. 2019. In vitro-in vivo extrapolation and hepatic clearance-dependent underprediction. J Pharm Sci. 108(7):2500–2504.
   PubMed Web of Science ®Google Scholar
• Burton RD, Hieronymus T, Chamem T, Heim D, Anderson S, Zhu X, Hutzler JM. 2018. Assessment of the biotransformation of low-turnover drugs in the HmicroREL human hepatocyte coculture model. Drug Metab Dispos. 46(11):1617–1625.
   PubMed Web of Science ®Google Scholar
• Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB, Jr., Rasmussen E, Chow V, Juan G, et al. 2018. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 36(6):1060–1071.
   PubMed Web of Science ®Google Scholar
• Chanteux H, Rosa M, Delatour C, Nicolaï J, Gillent E, Dell’Aiera S, Ungell AL. 2020. Application of azamulin to determine the contribution of CYP3A4/5 to drug metabolic clearance using human hepatocytes. Drug Metab Dispos. 48(9):778–787.
   PubMed Web of Science ®Google Scholar
• Chen X, Cui X, Pognan N, Quinlan M, Kapoor S, Rahmanzadeh G, Giovannini M, Marbury TC. 2022. Pharmacokinetics of capmatinib in participants with hepatic impairment: a phase 1, open-label, single-dose, parallel-group study. Br J Clin Pharmacol. 88(1):91–102.
   PubMed Web of Science ®Google Scholar
• Cobbina E, Lee MR, Leggio L, Akhlaghi F. 2021. A population pharmacokinetic analysis of PF-5190457, a novel ghrelin receptor inverse agonist in healthy volunteers and in heavy alcohol drinkers. Clin Pharmacokinet. 60(4):471–484.
   PubMed Web of Science ®Google Scholar
• Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P, Zinzani PL. 2019. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper. Hematol Oncol. 37(1):3–14.
   PubMed Web of Science ®Google Scholar
• Cuypers ML, Chanteux H, Gillent E, Bonnaillie P, Saunders K, Beckers C, Delatour C, Dell’Aiera S, Ungell AL, Nicolaï J. 2020. (-)-N-3-Benzylphenobarbital is superior to omeprazole and (+)-N-3-benzylnirvanol as a CYP2C19 inhibitor in suspended human hepatocytes. Drug Metab Dispos. 48(11):1121–1128.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Di L. 2019. Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacol Ther. 201:137–180.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, Loi CM. 2010. Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos. 38(4):641–654.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095.
   PubMed Web of Science ®Google Scholar
• Degorce SL, Aagaard A, Anjum R, Cumming IA, Diene CR, Fallan C, Johnson T, Leuchowius KJ, Orton AL, Pearson S, et al. 2020. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorg Med Chem. 28(23):115815.
   PubMed Web of Science ®Google Scholar
• Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, Jackson VM. 2017. Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol. 83(2):326–338.
   PubMed Web of Science ®Google Scholar
• Dhuria NV, Haro B, Kapadia A, Lobo KA, Matusow B, Schleiff MA, Tantoy C, Sodhi JK. 2021. Recent developments in predicting CYP-independent metabolism. Drug Metab Rev. 53(2):188–206.
   PubMed Web of Science ®Google Scholar
• Dick RA. 2018. Refinement of in vitro methods for identification of aldehyde oxidase substrates reveals metabolites of kinase inhibitors. Drug Metab Dispos. 46(6):846–859.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2015. Assessment report for LENVIMA (Procedure No EMEA/H/C/003727/0000). [accessed 2022 June 18]. https://www.ema.europa.eu/en/documents/assessment-report/lenvima-epar-public-assessment-report_en.pdf.
   Google Scholar
• European Medicines Agency. 2021. Assessment report for COPIKTRA (Procedure No EMEA/H/C/005381/0000). [accessed 2022 June 18]. https://www.ema.europa.eu/en/documents/assessment-report/copiktra-epar-public-assessment-report_en.pdf.
   Google Scholar
• Fan PW, Zhang D, Halladay JS, Driscoll JP, Khojasteh SC. 2016. Going beyond common drug metabolizing enzymes: case studies of biotransformation involving aldehyde oxidase, gamma-glutamyl transpeptidase, cathepsin B, flavin-containing monooxygenase, and ADP-Ribosyltransferase. Drug Metab Dispos. 44(8):1253–1261.
   PubMed Web of Science ®Google Scholar
• Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, Jaap van Lier J, Borell H, Meissner A, Camenisch G, et al. 2020. Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite. Drug Metab Dispos. 48(10):873–885.
   PubMed Web of Science ®Google Scholar
• Grant DM, Blum M, Beer M, Meyer UA. 1991. Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol. 39(2):184–191.
   PubMed Web of Science ®Google Scholar
• Hanioka N, Saito K, Isobe T, Ohkawara S, Jinno H, Tanaka-Kagawa T. 2021. Favipiravir biotransformation in liver cytosol: species and sex differences in humans, monkeys, rats, and mice. Biopharm Drug Dispos. 42(5):218–225.
   PubMed Web of Science ®Google Scholar
• Heinemann A, Wischhusen F, Puschel K, Rogiers X. 1999. Standard liver volume in the Caucasian population. Liver Transpl Surg. 5(5):366–368.
   PubMedGoogle Scholar
• Huang L, Be X, Berry L, Moore E, Janosky B, Wells M, Pan WJ, Zhao Z, Lin MH. 2011. In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases. Xenobiotica. 41(5):400–408.
   PubMed Web of Science ®Google Scholar
• Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB. 2012. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos. 40(2):267–275.
   PubMed Web of Science ®Google Scholar
• Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T. 2014. Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos. 42(8):1326–1333.
   PubMed Web of Science ®Google Scholar
• Jancova P, Anzenbacher P, Anzenbacherova E. 2010. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 154(2):103–116.
   PubMed Web of Science ®Google Scholar
• Jensen KG, Jacobsen AM, Bundgaard C, Nilausen DO, Thale Z, Chandrasena G, Jorgensen M. 2017. Lack of exposure in a first-in-man study due to aldehyde oxidase metabolism: investigated by use of 14C-microdose, humanized mice, monkey pharmacokinetics, and in vitro methods. Drug Metab Dispos. 45(1):68–75.
   PubMed Web of Science ®Google Scholar
• Jimenez HN, Li G, Doller D, Grenon M, White AD, Guo M, Ma G, inventors. 2010. Adamantyl diamide derivatives and uses of the same. Patent number: WO 2010/011570 A1.
   Google Scholar
• Kaye B, Offerman JL, Reid JL, Elliott HL, Hillis WS. 1984. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica. 14(12):935–945.
   PubMed Web of Science ®Google Scholar
• Kozminski KD, Selimkhanov J, Heyward S, Zientek MA. 2021. Contribution of extrahepatic aldehyde oxidase activity to human clearance. Drug Metab Dispos. 49(9):743–749.
   PubMed Web of Science ®Google Scholar
• Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA. 2002. Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 32(10):835–847.
   PubMed Web of Science ®Google Scholar
• Lang DH, Rettie AE. 2000. In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol. 50(4):311–314.
   PubMed Web of Science ®Google Scholar
• Lee MR, Tapocik JD, Ghareeb M, Schwandt ML, Dias AA, Le AN, Cobbina E, Farinelli LA, Bouhlal S, Farokhnia M, et al. 2020. The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study. Mol Psychiatry. 25(2):461–475.
   PubMed Web of Science ®Google Scholar
• Li AC, Cui D, Yu E, Dobson K, Hellriegel ET, Robertson P. Jr. 2019. Identification and human exposure prediction of two aldehyde oxidase-mediated metabolites of a methylquinoline-containing drug candidate. Xenobiotica. 49(3):302–312.
   PubMed Web of Science ®Google Scholar
• Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens F. 2015. The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species-specific insoluble metabolite formation. Clin Cancer Res. 21(10):2297–2304.
   PubMed Web of Science ®Google Scholar
• Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, Hay JL, Groeneveld GJ, Butt RP. 2018. Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. Br J Clin Pharmacol. 84(2):301–309.
   PubMed Web of Science ®Google Scholar
• Manevski N, King L, Pitt WR, Lecomte F, Toselli F. 2019. Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery. J Med Chem. 62(24):10955–10994.
   PubMed Web of Science ®Google Scholar
• Mao Z, Wu Y, Li Q, Wang X, Liu Y, Di X. 2018. Aldehyde oxidase-dependent species difference in hepatic metabolism of fasudil to hydroxyfasudil. Xenobiotica. 48(2):170–177.
   PubMed Web of Science ®Google Scholar
• Nicolaï J, Chapy H, Gillent E, Saunders K, Ungell AL, Nicolas JM, Chanteux H. 2020. Impact of in vitro passive permeability in a P-gp-transfected LLC-PK1 model on the prediction of the rat and human unbound brain-to-plasma concentration ratio. Pharm Res. 37(9):175.
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Watanabe T, Bando K. 2019. Quantitative prediction of human hepatic clearance for P450 and non-P450 substrates from in vivo monkey pharmacokinetics study and in vitro metabolic stability tests using hepatocytes. AAPS J. 21(2):20.
   PubMed Web of Science ®Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 283(1):46–58.
   PubMed Web of Science ®Google Scholar
• Obach RS, Huynh P, Allen MC, Beedham C. 2004. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol. 44(1):7–19.
   PubMed Web of Science ®Google Scholar
• Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. 2004. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 44(2):158–162.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. 2005. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 44(9):879–894.
   PubMed Web of Science ®Google Scholar
• Perera T, Lavrijssen T, Janssens B, Geerts T, King P, Mevellec L, Cummings M, Lu T, Johnson D, Page M. 2008. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. Cancer Res. 68 (9_Supplement):4837.
   Google Scholar
• Ramanathan S, Jin F, Sharma S, Kearney BP. 2016. Clinical pharmacokinetic and pharmacodynamic profile of idelalisib. Clin Pharmacokinet. 55(1):33–45.
   PubMed Web of Science ®Google Scholar
• Rendic SP, Crouch RD, Guengerich FP. 2022. Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. Arch Toxicol. 96(8):2145–2246.
   PubMed Web of Science ®Google Scholar
• Rosen AS, Fournie P, Darwish M, Danjou P, Troy SM. 1999. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos. 20(3):171–175.
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ, Graham GG. 1973. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm. 1(2):123–136.
   PubMedGoogle Scholar
• Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME. 1995. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol. 50(9):1385–1389.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Tayama Y, Sugihara K, Kitamura S, Ohta S. 2015. Significance of aldehyde oxidase during drug development: effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet. 30(1):52–63.
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, Scherle PA, Punwani NG, Williams WV, Yeleswaram S. 2011. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 51(12):1644–1654.
   PubMed Web of Science ®Google Scholar
• Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, et al. 2010. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 38(11):2023–2031.
   PubMed Web of Science ®Google Scholar
• Skerratt SE, Andrews M, Bagal SK, Bilsland J, Brown D, Bungay PJ, Cole S, Gibson KR, Jones R, Morao I, et al. 2016. The discovery of a potent, selective, and peripherally restricted Pan-Trk inhibitor (PF-06273340) for the treatment of pain. J Med Chem. 59(22):10084–10099.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Benet LZ. 2021. Successful and unsuccessful prediction of human hepatic clearance for lead optimization. J Med Chem. 64(7):3546–3559.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Jones C, Ferguson D, Middleton BJ, Projean D, Floby E, Bylund J, Afzelius L. 2012. Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica. 42(9):841–853.
   PubMed Web of Science ®Google Scholar
• Sonawane D, Sahu AK, Jadav T, Sengupta P. 2022. UHPLC-Q-TOF-MS/MS-based metabolite profiling of duvelisib and establishment of its metabolism mechanisms. Biomed Chromatogr. 36(4):e5314.
   PubMed Web of Science ®Google Scholar
• Strelevitz TJ, Orozco CC, Obach RS. 2012. Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos. 40(7):1441–1448.
   PubMed Web of Science ®Google Scholar
• Therapeutic Goods Administration. 2015. Australian public assessment report for idelalisib (Submission Number PM-2013-04151-1-4). [accessed 2022 June 18]. https://www.tga.gov.au/sites/default/files/auspar-idelalisib-150714.pdf.
   Google Scholar
• U.S. Food & Drug Administration. 2016. Drug development and drug interactions | Table of substrates, inhibitors and inducers. [accessed 2022 July 27]. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table1.
   Google Scholar
• Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. 2004. Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos. 32(4):413–423.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC. 2012. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos. 40(5):1051–1065.
   PubMed Web of Science ®Google Scholar
• Waters NJ, Jones R, Williams G, Sohal B. 2008. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci. 97(10):4586–4595.
   PubMed Web of Science ®Google Scholar
• Wellaway CR, Baldwin IR, Bamborough P, Barker D, Bartholomew MA, Chung CW, Dumpelfeld B, Evans JP, Fazakerley NJ, Homes P, et al. 2022. Investigation of janus kinase (JAK) inhibitors for lung delivery and the importance of aldehyde oxidase metabolism. J Med Chem. 65(1):633–664.
   PubMed Web of Science ®Google Scholar
• Winiwarter S, Chang G, Desai P, Menzel K, Faller B, Arimoto R, Keefer C, Broccatell F. 2019. Prediction of fraction unbound in microsomal and hepatocyte incubations: a comparison of methods across industry datasets. Mol Pharm. 16(9):4077–4085.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, et al. 2018. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 36(31):3101–3109.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li L, Wang Y, Xing J, Zhou L, Zhong D, Luo X, Jiang H, Chen K, Zheng M, et al. 2017. Aldehyde oxidase mediated metabolism in drug-like molecules: a combined computational and experimental study. J Med Chem. 60(7):2973–2982.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Liu MY, Kurogi K, Sakakibara Y, Saeki Y, Suiko M, Liu MC. 2015. Sulphation of acetaminophen by the human cytosolic sulfotransferases: a systematic analysis. J Biochem. 158(6):497–504.
   PubMed Web of Science ®Google Scholar
• Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. 2007. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos. 35(3):501–502.
   PubMed Web of Science ®Google Scholar
• Yang LP, Keating GM. 2012. Ruxolitinib: in the treatment of myelofibrosis. Drugs. 72(16):2117–2127.
   PubMed Web of Science ®Google Scholar
• Yang X, Johnson N, Di L. 2019. Evaluation of cytochrome P450 selectivity for hydralazine as an aldehyde oxidase inhibitor for reaction phenotyping. J Pharm Sci. 108(4):1627–1630.
   PubMed Web of Science ®Google Scholar
• Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. 2005. A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom. 19(2):250–254.
   PubMed Web of Science ®Google Scholar
• Zhao L, Pickering G. 2011. Paracetamol metabolism and related genetic differences. Drug Metab Rev. 43(1):41–52.
   PubMed Web of Science ®Google Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. 2010. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos. 38(8):1322–1327.
   PubMed Web of Science ®Google Scholar